Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
Can online therapy finally close New Mexico’s mental health gap? SkyMD bets big on statewide virtual care
SkyMD launches statewide online therapy in New Mexico. Find out what this expansion means for access, regulation, and teletherapy adoption.
What the FDA decision on PTC Therapeutics’ Translarna reveals about Duchenne muscular dystrophy drug approvals
PTC Therapeutics has withdrawn its U.S. filing for Translarna. Find out what this means for Duchenne drug development and FDA expectations.
Why Hurricane Ventures’ investment in BioReact highlights the next phase of digital bioprocessing
UTulsa-backed BioReact targets bioprocess inefficiencies with AI analytics. Discover what this investment could change for biopharma development and manufacturing.
Can Innovent’s IBI354 replace chemotherapy in first-line HER2-positive metastatic breast cancer
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.
What CARsgen Therapeutics’ RMB370m manufacturing plan reveals about CAR-T execution risk
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.
How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.
What Lilly’s Orna Therapeutics deal means for immune reset strategies
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone […]
What Kailera Therapeutics and Hengrui Pharma’s Phase 2 ribupatide results reveal about oral GLP-1 viability
Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.
Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.